Phaseline

Companies › Beacon Therapeutics

Beacon Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 3 Phase 2, 1 Phase 1; Ophthalmology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
rAAV2tYF-GRK1-RPGR
Adeno-associated virus vector expressing human RPGR gene
RPGRPhase 2X-Linked Retinitis PigmentosaFeb 2027
Laruparetigene zovaparvovec (AGTC-501)
Adeno-associated virus vector expressing human RPGR gene
RPGRPhase 2X-Linked Retinitis Pigmentosa (XLRP); X-Linked Retinitis PigmentosaDec 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03316560rAAV2tYF-GRK1-RPGRPhase 1X-Linked Retinitis PigmentosaOphthalmologyNov 2023
NCT06333249rAAV2tYF-GRK1-RPGRPhase 2X-Linked Retinitis PigmentosaOphthalmologyFeb 2027
NCT07174726Laruparetigene zovaparvovec (AGTC-501)Phase 2X-Linked Retinitis Pigmentosa (XLRP)OphthalmologyDec 2029
NCT04850118Laruparetigene zovaparvovec (AGTC-501)Phase 2X-Linked Retinitis PigmentosaOphthalmologyOct 2031

Targets

RPGR (2)

Companies with the same targets

MeiraGTx Ocular UK 4D Molecular Therapeutics

Companies built like this

MeiraGTx Ocular UK jCyte NovaSight Emmecell Price Vision Group

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.